Using Human Xenografts to Test New Prostate Cancer Treatments
Author Information
Author(s): van Weerden W M, Bangma C, de Wit R
Primary Institution: Erasmus MC, Rotterdam, The Netherlands
Hypothesis
Can human xenograft models effectively assess new therapeutic combinations for hormone refractory prostate cancer?
Conclusion
Human xenograft models can significantly improve the selection of promising new treatments for hormone refractory prostate cancer.
Supporting Evidence
- Docetaxel-based chemotherapy has improved survival in hormone refractory prostate cancer.
- Xenograft models allow for the validation of biomarkers like PSA in treatment response.
- The review highlights the need for fast-track screening systems for new therapies.
Takeaway
Scientists are using special models made from human prostate cancer cells to quickly find the best new treatments for prostate cancer.
Methodology
The review discusses the use of human xenograft models to evaluate new therapeutic agents and combinations for prostate cancer.
Limitations
The review does not provide specific limitations but notes the challenges in correlating surrogate endpoints with overall survival.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website